Multipotent stem cells and uses thereof
The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1, TWIST, KLF-4 and Stella but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCF4, CD133 or an SSEA. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiating the stem cells, are also provided.
1. A method of enhancing recovery from joint surgery, comprising administering to the joint during surgery to repair the joint a composition comprising stem or progenitor cells that express a stem cell transcription factor but do not detectably express MHC Class I or cell surface markers CD13, CD44, CD45, and CD90 in an amount effective to enhance recovery, and a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein the stem cells are capable of proliferating and differentiating into ectoderm, mesoderm and endoderm.
3. The method of claim 1 , wherein the stem cells are synovial fluid derived, blood derived or tissue derived.
4. The method of claim 1 , wherein the stem cells are isolated from a mammal.
5. The method of claim 4 , wherein the stem cells are isolated from a human.
6. The method of claim 4 , wherein the stem cells are isolated from an adult mammal.
7. The method of claim 1 , wherein the stem cells are autologous with respect to a recipient undergoing the joint surgery.
8. The method of claim 1 , wherein the stem cells are allogeneic with respect to a recipient undergoing the joint surgery.
9. The method of claim 1 , wherein the stem cells are committed to differentiate.
10. The method of claim 1 , wherein the composition further comprises at least one subpopulation of differentiated progeny cells.
11. The method of claim 1 , wherein the population of cells expresses a stem cell transcription factor selected from the group consisting of Oct-4, Nanog, Sox-2, Rex-1, GDF-3 and Stella.